The unmet clinical need of novel antifungal drugs
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The global impact of fungal infections on human health has recently been highlighted by several important publications,1,2 and advocacy groups.3 Although several factors undoubtedly contribute to t...
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, only three primary classes of agents are used to treat invasive fungal infections5: polyenes (for example, amphotericin B); azoles (for example, fluconazole) and echinocandins (for example, caspofungin) (Table 1).”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [5]
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Tackling Human Fungal Infections
Brown, G. D., Denning, D. W., & Levitz, S. M. (2012) · Science · doi:10.1126/science.1222236 · Cited by 619
Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Roemer, T., & Krysan, D. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019703 · Cited by 593
Self-citationCombinatorial strategies for combating invasive fungal infections
Spitzer, M., Robbins, N., & Wright, G. D. (2017) · Virulence · doi:10.1080/21505594.2016.1196300 · Cited by 218
Rhein, J., Morawski, B. M., Hullsiek, K. H., Nabeta, H. W., Kiggundu, R., Tugume, L., Musubire, A., Akampurira, A., Smith, K. D., Alhadab, A., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00074-8 · Cited by 183 · cited 1×
“most successfully with respect to the treatment of cryptococcal meningitis.(19) Here, Lopez-Ribot and coauthors(20) describe the antifungal activity of the rheumatoid arthritis therapy auranofin as a potentially”
MethodTargeting Candida albicans filamentation for antifungal drug development
Vila, T., Romo, J. A., Pierce, C. G., McHardy, S. F., Saville, S. P., & Lopez-Ribot, J. L. (2017) · Virulence · doi:10.1080/21505594.2016.1197444 · Cited by 174
Juvvadi, P. R., Lee, S. C., Heitman, J., & Steinbach, W. J. (2017) · Virulence · doi:10.1080/21505594.2016.1201250 · Cited by 172
Current status of HIV/AIDS in the ART era
Yoshimura, K. (2016) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2016.10.002 · Cited by 163 · cited 1×
“used to treat HIV and 2 of these agents have been developed since the introduction of the most recently introduced antifungal class, the echinocandins.(5) Amphotericin B was developed in the late 1950s and remains”
BackgroundNew facets of antifungal therapy
Chang, Y.-L., Yu, S.-J., Heitman, J., Wellington, M., & Chen, Y.-L. (2017) · Virulence · doi:10.1080/21505594.2016.1257457 · Cited by 161 · cited 2×
“broader discussion of new developments associated with established antifungal drugs.(8) Although combination therapy has been widely”
BackgroundConfronting the challenges of natural product-based antifungal discovery
Roemer, T., Xu, D., Singh, S. B., Parish, C. A., Harris, G., Wang, H., Davies, J. E., & Bills, G. F. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.009 · Cited by 147 · cited 1×
“chemical matter targeting the same fungal processes.(16) OTSB-approaches like these should circumvent the convergent chemical evolution that has emerged from the previously pursued approaches.”
Background
Research works printed but not linked: 1
- Clancy CJ, 2016, Clin Infect Dis, 141-143
Cited by
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Self-citationUltra-fast proteomics with Scanning SWATH
Messner, C. B., Demichev, V., Bloomfield, N., Yu, J. S. L., White, M., Kreidl, M., Egger, A.-S., Freiwald, A., Ivosev, G., Wasim, F., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00860-4 · Cited by 308
Geddes‐McAlister, J., & Shapiro, R. S. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13739 · Cited by 159
Ji, X., Yang, H., Liu, W., Ma, Y., Wu, J., Zong, X., Yuan, P., Chen, X., Yang, C., Li, X., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c01379 · Cited by 104
Elias, R., Benhamou, R. I., Jaber, Q. Z., Dorot, O., Zada, S. L., Oved, K., Pichinuk, E., & Fridman, M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.003 · Cited by 78
Metadata
- Authors
- Krysan, D. J.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- Krysan, Damian J.
- ORCID
- Krysan, Damian J.
- Venue
- Virulence
- Publisher
- Informa UK Limited
- Published
- 2017-01-17
- Volume
- 8
- Issue
- 2
- Pages
- 135-137
- ISSN
- 2150-5594 (ISSN-L)
- 2150-5608
- PMC
- PMC5354155
- OpenAlex
- W2578872550
- Cited by
- 37
- References
- 19
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 8 · 2023: 6 · 2022: 2 · 2021: 5 · 2020: 6 · 2019: 2 · 2018: 4
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Virulence (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- antifungal agents, fungal infection, unmet clinical needs, antifungal resistance, drug development
- MeSH terms
- Antifungal Agents, Humans, Mycoses, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The unmet clinical need of novel antifungal drugs. https://app.cochat.ai/papers/10.1080/21505594.2016.1276692
- The paper
- Krysan, D. J. (2017). The unmet clinical need of novel antifungal drugs. Virulence. https://doi.org/10.1080/21505594.2016.1276692
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.